The concept has been around for more than a century, but recent advances in the field are causing numerous experts to say its widely underused. The goal of allergen immunotherapy (AIT) is to induce a specific immune tolerance by confronting patients with increasing levels of allergens. AIT developers are now working on improving efficacy and safety, while at the same time trying to speed up the still lengthy process of desensitisation. Peanuts in particular are in the crosshairs, as they cause one of the most life-threatening common allergies in humans.
Allergies: Public Enemy Number One
BackgroundThe concept has been around for more than a century, but recent advances in the field are causing numerous experts to say its widely underused. The goal of allergen immunotherapy (AIT) is to induce a specific immune tolerance by confronting patients with increasing levels of allergens. AIT developers are now working on improving efficacy and safety, while at the same time trying to speed up the still lengthy process of desensitisation. Peanuts in particular are in the crosshairs, as they cause one of the most life-threatening common allergies in humans.
Exscientia inks €37m contract with GSK
Latest NewsBritish pharma giant GlaxoSmithKline has secured access to Ex Scientia Ltd (Exscientia)s artificial intelligence (AI)-driven drug discovery platform.
Breaking therapy resistance of follicular lymphoma
Latest NewsSwiss researchers have found a way to prevent the multiple disease relapses after responses to follicular lymphoma therapy.
Tiziana Life Sciences: Putting research first
AppointmentsAIM-listed Tiziana Life Sciences has a new head: The clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases appointed Kunwar Shailubhai Chief Executive Officer and Chief Scientific Officer.
AML: Cellectis testing allogenic CAR-T cell therapy
Latest NewsGenome editing specialist Cellectis has kicked off clinical tests in the US for the very first of-the-shelf CAR-T cell therapy in acute myeloid leukaemia.
Diabetes: J&J and Seventure Partners launch investment
Latest NewsEuropean venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, the companys app analyses the individual microbiome to predict blood sugar responses to thousands of different foods.
€66m Life Sciences Fund focused on Germany and Benelux
Latest NewsVenture Capitalist Biogeneration Ventures has exceeded the target size of its life sciences fund BGV III through investments from the European Investment Banks InnovFin Equity Facility and the Dutch Venture Initiative II.
Ablynx: Chief of business
AppointmentsBelgian biopharmaceutical company Ablynx named Markus L.E. Ewert Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead the Company’s business development and corporate strategy activities and become a member of the Executive Committee.
CHMP recommends several biologics
Latest NewsThe European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has recommended two antivirals, one biosimilar and two cancer meds for approval at its June meeting.
Update of bioeconomy strategy unsure
BackgroundUncertainty regarding the amount of future funding and political support from the European Commission for the bioeconomy is set to hamper investments into the switch from oil-based industry production to renewable, bio-based manufacture in Europe. The schedule for the review of the bioeconomy strategy has been delayed until the end of 2017. More importantly, it is not yet certain if the strategy will be updated.